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ONE SHOT - single shot radiotherapy for
localized prostate cancer: study protocol of
a single arm, multicenter phase I/II trial
Thomas Zilli1,2* , Marta Scorsetti3,4, Daniel Zwahlen5, Ciro Franzese4, Robert Förster6, Niccolò Giaj-Levra7,
Nikolaos Koutsouvelis1, Aurelie Bertaut8, Michel Zimmermann5, Giuseppe Roberto D’Agostino4, Filippo Alongi7,9,
Matthias Guckenberger6 and Raymond Miralbell1,2
Abstract
Background: Stereotactic body radiotherapy (SBRT) is an emerging treatment alternative for patients with localized
prostate cancer. Promising results in terms of disease control and toxicity have been reported with 4 to 5 SBRT
fractions. However, question of how far can the number of fractions with SBRT be reduced is a challenging research
matter. As already explored by some authors in the context of brachytherapy, monotherapy appears to be feasible
with an acceptable toxicity profile and a promising outcome. The aim of this multicenter phase I/II prospective
trialis to demonstrate early evidence of safety and efficacy of a single-fraction SBRT approach for the treatment of
localized disease.
Methods: Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional
zone will be treated with a single SBRT fraction of 19 Gy to the whole prostate gland with urethra-sparing (17 Gy).
Intrafractional motion will be monitored with intraprostatic electromagnetic transponders. The primary endpoint of the
phase I part of the study will be safety as assessed by CTCAE 4.03 grading scale, while biochemical relapse-free survival
will be the endpoint for the phase II. The secondary endpoints include acute and late toxicity, quality of life,
progression-free survival, and prostate-cancer specific survival.
Discussion: This is the first multicenter phase I/II trial assessing the efficacy and safety of a single-dose SBRT treatment
for patients with localized prostate cancer. If positive, results of ONE SHOT may help to design subsequent phase III trials
exploring the role of SBRT monotherapy in the exclusive radiotherapy treatment of localized disease.
Trial registration: Clinicaltrials.gov identifier: NCT03294889; Registered 27 September 2017.
Keywords: Prostate cancer, Stereotactic body radiotherapy, Urethra-sparing, Single fraction, Quality of life,
Electromagnetic transponders
Background
Total dose and dose per fraction play an important role
in the curative treatment of prostate cancer with radio-
therapy (RT). Modern image-guided external RT allows
safe dose escalation for prostate cancer. Doses above
74 Gy with conventional fractionation (2 Gy/day) have
been shown to be beneficial. There are strong
radiobiological considerations that suggest that treat-
ment with a small number of large fractions (hypofrac-
tionation) may increase the therapeutic ratio of RT for
prostate cancer.
The “α/β” ratio (i.e., cell sensitivity/cell repair) is a key
parameter of the cell-survival linear-quadratic (LQ)
model that purportedly defines the sensitivity of each tis-
sue (healthy or tumoral) to changes in treatment frac-
tionation. Prostate cancer cells may have a low α/β ratio
(i.e.,~ 1.5 Gy), lower than that of most tumors or even of
the late-responding normal tissues surrounding the
tumor, the rectum and the bladder (α/β ratio 3–5 Gy)
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[1]. Thus, hypofractionation may increase the tumor cell
killing effect with relatively less toxic effect on the sur-
rounding late responding normal tissues compared to
conventional fractionation. Several authors have re-
ported their respective experiences with moderate hypo-
fractionation (i.e., dose per fraction 2.5 Gy to 4 Gy) for
prostate cancer confirming the equivalence in terms of
disease control and tolerance compared to standard frac-
tionated treatments [2–5].
Bio-mathematical models using large patient data sets
have focused on external beam RT schedules using less
than 4 Gy fractions. It deserves to be acknowledged that
the LQ model may not be predictive of cell survival and
isoeffects with doses per fraction above 3-4Gy. Indeed,
the predictions of the LQ model at very high dose/frac-
tion (extreme hypofractionation) may be somehow “am-
bivalent”, either overestimated (less repair of sublethal
damage thus a lower value for “β”) or underestimated
(increased indirect cell-death secondary to intravascular
endothelial damage). Staring from this background, clin-
ical research on extreme hypofractionation started some
15 years ago when stereotactic body RT (SBRT) technol-
ogy appeared as a treatment option against localized
prostate cancer competing with high-dose rate brachy-
therapy (HDR-BT).
Indeed, preliminary results on extreme hypofractiona-
tion with SBRT have been reported during the last few
years mainly for low-risk patients in single-institution
[6–8] or multi-institutional [9] series. Most frequently, 5
fractions of 7.25 Gy have been delivered for a total
equivalent dose to the tumor of 90 Gy in 2 Gy/fraction
(LQ model) and a success rate of > 90%, 5-year biochem-
ical relapse-free (bRFS) survival rates [10]. Data pub-
lished so far for prostate SBRT have shown, although
with a limited follow-up, late grade 3 toxicity rates for
rectal and genitourinary (GU) toxicity lying within a ≤
3% range [8, 11, 12]. Although, caution is recommended
to avoid passing a too optimistic message regarding the
potential biological benefits of extreme hypofractiona-
tion for prostate cancer (i.e., more cure with less side ef-
fects), financial and logistical advantages can
undoubtedly be foreseen. In fact, a drop from 40 or
more treatments to 5 or less sessions may reduce the
cost of external beam RT, will increase the availability of
treatment slots in otherwise busy departments (import-
ant issue in countries with limited resources), and sig-
nificantly improve patient’s convenience.
The question of how far can the number of fractions
with SBRT be reduced is an exciting research matter
with an undoubtful goal, face the challenge of assessing
the potential for cure of prostate cancer patients with a
single and unique fraction of high dose irradiation simi-
lar to what is already undertaken with radiosurgery
against brain, lung, and liver targets. Such type of effort
has already been attempted with HDR-BT. Recently,
Prada et al. [13] reported a relatively disappointing 66%
6-year bRFS survival though a very good tolerance after
a single interstitial application of 19 Gy to the prostate.
Reasons for this suboptimal result may be related, for in-
stance, to a suboptimal dose-distribution with HDR-BT
compared to SBRT. Hoskin et al. have recently published
the results on 49 patients treated with a single fraction
of HDR-BT to 19/20 Gy [14]. With 49 months median
follow-up, the 4-year estimates of grade-3 GU and
gastrointestinal (GI) toxicity was 2% and 0%, respect-
ively, with no grade 4 events, while the 4-year bRFS was
94%. Similarly, Morton et al. confirmed with a median
follow-up time of 20 months the good tolerance of a sin-
gle 19 Gy single HDR-BT fraction in terms of toxicity
and impact on quality of life (QoL) [15] and Krauss et al.
reported a 3-year bRFS rate of 93% [16], similar to re-
sults observed by Hoskin et al. In conclusion, for the au-
thors one single fraction HDR-BT is feasible, weakly
toxic, and with promising preliminary results.
Although, the effects are mostly encouraging, only
controlled studies are able to properly address the im-
pact of single fraction SBRT in prostate cancer out-
comes. Therefore, a phase I/II approach will be a
properly controlled study to demonstrate early evidence
of safety and efficacy of the intervention and substantiate
further the role of a single-fraction SBRT approach. If
positive, the results of ONE SHOT will help determine
the design of subsequent phase III trials in the exclusive
RT setting for the treatment of localized disease.
Methods/Design
This study was approved by the Ethics committee of the
Geneva University Hospital (2017–01236) and is regis-
tered on clinicaltrials.gov (NCT03294889). This is a
phase I/II, prospective, multicenter, single-arm study.
Phase I, safety evaluation
The main objective of the phase I trial is to determine if
a single fraction SBRT, with a dose of 19 Gy, is safe and
well tolerated by assessing the occurrence of Grade ≥ 3
acute adverse events (AE) during the first 3 months.
Phase II, efficacy evaluation
The main objective of the phase II trial is to determine if
a single fraction SBRT, with a dose of 19 Gy, is an effect-
ive treatment option by assessing bRFS at 3 years.
Objectives
Primary endpoint of the phase I trial Grade ≥ 3GU
and GI acute AE will be assessed during the first three
months following the single fraction treatment. AEs will
be assessed according to National Cancer Institute
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Common Terminology Criteria for Adverse Events (NCI
CTCAE) v4.03. Special attention will be given to diarrhea,
fecal incontinence, proctitis, rectal hemorrhage, rectal
pain, hematuria, urinary frequency, urinary urgency,
urinary retention, urinary incontinence, and cystitis
non-infective. Persistent AE will be defined as any persist-
ent toxicity during the first 3 months post-treatment
(follow-up milestones: 1 week, 6 weeks, and 12 weeks).
Primary endpoint of the phase II trial bRFS, from time
of inclusion until biochemical progression (according to
recommendations of the Radiation Therapy Oncology
Group - American Society for Radiation Oncology (RTO-
G-ASTRO), the Phoenix Consensus Conference recom-
mendations) [17]:
 A rise by 2 ng/ml or more above the nadir prostate
specific antigen (PSA) confirmed by a second
observation taken 3–4 weeks later, where the nadir PSA
is defined as the lowest PSA value observed on study.
Secondary endpoints of the phase II trial
 Acute AE (during the first 3 months follow-up)
according to CTCAE v4.03
 Late AE (after 3 months follow-up) according to
CTCAE v4.03
 Progression free survival (PFS) defined as time from
inclusion until one of the following events,
whichever comes first:
 Biochemical progression
 Clinical progression defined as either local or
regional recurrence of the disease or the appearance
of distant metastases
 Death from any cause
 Start of another line of systemic anti-neoplastic therapy
 Clinical progression free-survival
 Local progression free-survival
 Time to further anti-cancer therapy defined as the
time from inclusion to the start of any type of
salvage treatment.
 Prostate cancer-specific survival (PCSS)
 Overall survival (OS)
 QoL evaluated using EPIC 26 (Expanded prostate
cancer index composite) [18], IPSS (International
Prostate Symptoms Score) [19], and IIEF-5
(International Index of Erectile Function) [20]
Inclusion criteria
– Written informed consent according to ICH/GCP
regulations before registration and prior to any trial
specific procedures
– Histologically confirmed adenocarcinoma of the
prostate without small cell features
– Tumor clinical stage cT1c-2c, pN0 or cN0, M0,
according to UICC TNM 2009
– Magnetic Resonance Imaging (MRI) staging must
confirm American Joint Committee on Cancer
(AJCC) stage T1, T2a, T2b, or T2c
– Gleason score at biopsy 3 + 3 or 3 + 4 (World Health
Organization, WHO 2016 Grade Groups 1, 2)
– PSA ≤15 ng/ml
– Age 18–85 years at time of registration
– WHO performance status 0–1
– IPSS ≤10 (alpha blockers allowed)
– MRI-based volume estimation of prostate gland ≤70 cc
– Patient agrees not to father a child during trial
treatment and during 6 months thereafter
Exclusion criteria
– Evidence of T3a, T3b, or T4 disease as assessed by MRI
– Positive lymph-nodes or metastatic disease from
prostate cancer on imaging studies.
– Significant tumor on the transitional zone as
assessed by MRI
– Previous or ongoing androgen deprivation therapy
– Impossibility to implant electromagnetic
transponders into the prostate
– History of hematologic or primary solid tumor
malignancy, unless in remission for at least 3 years
from registration with the exception of curatively
treated localized non-melanoma skin cancer
– Prior pelvic RT
– Previous surgery for prostate cancer
– Previous transurethral resection of the prostate
(< 12 weeks before registration)
– Hip prosthesis
– Severe or active co-morbidity likely to impact on the
advisability of SBRT
– Any other serious underlying medical, psychiatric,
psychological, familial, or geographical condition,
which in the judgment of the investigator may
interfere with the planned staging, treatment and
follow-up, affect patient compliance, or place the pa-
tient at high risk from treatment-related
complications
Intervention
In this trial, patients with localized prostate cancer are
registered to receive the following target SBRT dose:
 19 Gy in a single fraction to the whole prostate
gland ± proximal seminal vesicles
 17 Gy in a single fraction to the urethra planning-
risk volume (PRV)
Zilli et al. Radiation Oncology  (2018) 13:166 Page 3 of 8
Before the SBRT treatment, all patients will be im-
planted transrectally or transperineally under ultrasound
guidance with three electromagnetic transponders, the
Calypso® beacons (Varian Medical Systems, Palo Alto,
CA). Patients will be simulated a minimum of 4 days after
the implant and treated with an empty rectum and full
bladder. To help with the contouring of the urethra a 12
French Foley non-radiopaque catheter will be inserted be-
fore the CT simulation and before irradiation. Rigid or de-
formable co-registration with multi-parametric MRI is to
be used for contouring purposes.
The Clinical Tumor Volume (CTV) is defined as the
prostate +/− the proximal 2/3 of the seminal vesicles
(SV) based on the risk of SV involvement as determined
by the Roach score using a cutoff threshold of 15% [21].
The planning target volume (PTV) is defined as the
CTV plus 5 mm margins in all directions except for a
3 mm margin posteriorly towards the rectal wall. The
urethra PRV is defined on CT images by contouring a
12 French Foley catheter with a 2 mm isotropic rim ex-
pansion. Organs at risk (OAR) are contoured according
to RTOG guidelines [22] and include the bladder wall
and the rectal wall (both defined as a 5-mm internal
margin created from the external surface), the penile
bulb [23], and the proximal femurs. All patients will be
treated with megavoltage beams from a TrueBeam® lin-
ear accelerator (Varian Medical Systems, Palo Alto, CA)
with nominal photon energies ≥6 MV, 6 degrees of free-
dom couch, and a Calypso® localization system. The ir-
radiation technique is RapidArc® (Varian Medical
Systems, Palo Alto, CA), a rotational technique using a
flattening filter-free (FFF) modality with patients treated
in an isocentric setting.
Dose prescription, recording and reporting As volu-
metric modulated arc therapy (VMAT) techniques are
mandatory in this trial, the definition of volumes and the
dose reporting shall be in accordance with the ICRU
(International Commission on Radiation Units and
Measurements) report 83. The dose variation in the PTV
shall be assessed by the near-minimum dose (D98%) and
near-maximum dose (D2%). The proposed treatment veri-
fication schedule is presented in Fig. 1 using a threshold
limit for Calypso® of ±3 mm with geometric check limits
Fig. 1 Image-guided flowchart as per protocol
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set to 2 mm (geometrical residual) and rotations of 10°
(default values). Table 1 summarizes the dose constraints
for the OAR [24].
Radiation Therapy Quality Assurance (RTQA) A
RTQA program is based in Geneva and is an important
asset of this multicentric trial. Electronic submission and
assessment of target and OaR volumes, in addition to
treatment plans as well, is a major step before any treat-
ment can be validated and approved.
Follow-up
Patients are seen at day-5 after SBRT, at weeks 6 and 12,
every 6 months for 2 years post treatment, and yearly up to
5 years of follow-up. A clinical update and a physical exam
are conducted by recording any acute and/or late AE and
the sequential PSA measurements. IPSS, IIEF-5, and QoL
(EPIC-26 questionnaire) assessments are also performed.
Radiological investigations including mpMRI, bone scan,
choline-PET, and/or PSMA-PET will be repeated in case of
progression, either biochemical or clinical.
Statistical analysis
Sample size
Phase I, safety evaluation
Only acute GU and/or GI grade 3 or higher toxicity will
be considered for the safety evaluation. Three patients
will be treated and evaluated for toxicity at 3 months. If
the first 3 patients undergo any grade ≥ 3 toxicity or if 2
patients under go grade 4 toxicity, the trial will stop.
Otherwise, 3 additional patients will be recruited and
treated. If 2/6 patients or fewer present with grade 3 AE,
the trial will go on phase II and include 39 additional pa-
tients. Regarding these 6 patients, if one or more present
with grade 4 toxicity, a meeting of the Data Safety and
Monitoring Board (DSMB) will be carried on.
Phase II, efficacy evaluation
Based on published SBRT results on 5 fraction-trials and
on one series of HDR-BT with 19 Gy single shot, a
3-yearsbRFS of 96% may be expected. Assuming this hy-
pothesis and an expected dropout rate of 10%, 45 pa-
tients (including the 6 included in the phase I study) will
allow evaluating 3-year bRFS with a 97.5% lower
one-sided confidence interval and a width of the interval
of 0.06 (upper bound = 90%).
Data analysis
Data description will be performed using the mean,
standard deviation, median, and range for quantitative
variables and the percentage for qualitative ones.
Phase I
Safety analyses shall be performed on the safety-evaluable
population, defined as all subjects treated with the single
shot SBRT. Toxicity and grade will be described at each
follow-up visit according to the specificity of every
Table 1 Dose constraints
Structure Standardized nomenclature Dosimetric Parameter Per Protocol Acceptable Variation
PTV_19 PTV_19 D98% (Dnear min) ≥ 95% (i.e. 18 Gy)
D2% (Dnear max) ≤ 107% (ie. 20.3Gy) D5% ≤ 107%, D2% ≤ 110%
Rectal_wall Rectal_wall V9.5Gy (50%) < 40% 40–50%
V15Gy (80%) < 15% 15–20%
V17Gy (90%) (NTD 68 Gy) < 10% < 15%
V19Gy (100%) (NTD 83.6 Gy) < 5% < 10%
V20Gy (105%) (NTD 92 Gy) < 1 cc
Bladder_wall Bladder_wall V9.5Gy (50%) < 50% 50–60%
V15Gy (80%) < 20% 20–30%
V17Gy (90%) (NTD 68 Gy) < 15% 15–20%
V19Gy (100%) (NTD 83.6 Gy) < 10% < 15%
V20Gy (105%) (NTD 92 Gy) < 1 cc
Femurs (each) Femur_Rt
Femur_Lt
V14Gy (NTD 48 Gy) < 5% 5–10%
Penile bulb Penile_bulb V14Gy (NTD 48 Gy) < 5% 5–10%
Urethra PRV Urethra_PRV D98% (Dnear min) ≥ 95% (i.e. 16.2 Gy)
D5% ≤ 107% (i.e. 18.2 Gy)
D2% (Dnear max) ≤ 110% (i.e. 18.7 Gy)
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assessed endpoint, including the number and fraction of
patients with at least one AE.
Phase II- statistical analysis of the primary endpoint
Efficacy analyses will be performed on an intention to
treat basis (i.e., involving those patients following the
major inclusion criteria and repeated one per protocol
set). The primary endpoint is 3-years bRFS. bRFS, and its
97.5% one-sided confidence interval (CI), will be deter-
mined using the Kaplan Meier method. If the expected
value of 96% isn’t included in this interval, the efficacy of
the experimental treatment will be questioned.
Phase II - statistical analysis of the secondary endpoints
Toxicity analyses will be performed. As for acute tox-
icity, late AE and grading will be reported at each fol-
low up visit. Median survival time and its 95% bilateral
confidence intervals (PFS, clinical PFS, local PFS, OS,
and PCSS) will be determined using the Kaplan Meier
method. The rate of survival will be given at 1, 2, 3, and
5 years. Univariate and multivariate Cox regression
models will be fit to assess the effect of relevant base-
line clinical and pathologic features on bRFS, PFS, and
OS. Hazard ratio (HR) will be given with their 95% con-
fidence intervals. Median follow-up will be estimated
using the reverse Kaplan Meier method. QoL scores
(EPIC, IPSS, IIEF-5) will be described at each clinical
surveillance follow-up time by the mean, standard devi-
ation, median, and range. Domain scores will be calcu-
lated only if sufficient items are completed in
accordance with the relevant scoring manual. Mixt
models will be used to characterize changes in QoL
across time taken into account for confounding clinical
and pathologic factors. All statistical analysis will be
performed with SAS 9.4. p-values less than 5% will be
considered as significant.
Discussion
Optimal management of localized low- or intermediate
risk prostate cancer remains a challenging situation, with
different treatment options available ranging from active
surveillance to radical treatment [25]. Considering that
patients under active surveillance have a greater risk of
disease progression and metastases compared to defini-
tive treatments [26], the choice of the more appropriate
curative option is a crucial issue for clinicians.
SBRT represents a valid treatment option for these pa-
tients, combing a good toxicity profile, promising disease
control rates, and limited impact on QoL. Recently re-
ported, preliminary results of the Scandinavian phase III
HYPO-RT-PC trial found in 1200 intermediate-risk
prostate cancer patients similar biochemical control
rates and toxicities results with extreme hypofractiona-
tion (42.7 Gy in seven fractions of 6.1 Gy over two and a
half weeks) compared to standard fractionation 78 Gy
[27]. However, the optimal SBRT fractionation schedule
for curative treatment of patients with localized prostate
cancer is, so far, unknown. Based on the promising re-
sults of HDR-BT monotherapy treatments [15, 28, 29],
single-shot SBRT may represent an appealing treatment
modality for prostate cancer patients.
To our knowledge, ONE SHOT is the first phase I/II
trial assessing the efficacy and safety of a single-dose
SBRT treatment for patients with localized prostate can-
cer in a multicenter setting. ONE SHOT proposes the
same treatment technique under a strict RTQA protocol
for all patients. By reducing significantly the beam-on
time [30], our single shot linac-based FFF VMAT tech-
nique with intra-fractional control motion is expected to
guarantee not only treatment reproducibility [31] but
also minimize intra-fraction dose uncertainties [32].
Moreover, the implementation of patient-reported out-
come using validated questionnaires will provide a reli-
able evaluation of the clinical impact of a single-dose
SBRT by reporting a longitudinal follow-up on the
long-term of radiation-induced side effects compared to
physician-reported data.
While waiting for results of presently ongoing ran-
domized phase III trials comparing SBRT with other
fractionation or treatment, results of the ONE SHOT
trial, if positive, may help to design subsequent studies
exploring the role of SBRT monotherapy in the exclusive
RT treatment of localized disease.
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